Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
27
10
2020
accepted:
16
12
2020
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
25
2
2021
Statut:
epublish
Résumé
During the past few years, our understanding of molecular mechanisms and cellular interactions relevant to malignant blood cell disorders has improved substantially. New insights include a detailed knowledge about disease-initiating exogenous factors, endogenous (genetic, somatic, epigenetic) elicitors or facilitators of disease evolution, and drug actions and interactions that underlie efficacy and adverse event profiles in defined cohorts of patients. As a result, precision medicine and personalized medicine are rapidly growing new disciplines that support the clinician in making the correct diagnosis, in predicting outcomes, and in optimally selecting patients for interventional therapies. In addition, precision medicine tools are greatly facilitating the development of new drugs, therapeutic approaches, and new multiparametric prognostic scoring models. However, although the emerging roles of precision medicine and personalized medicine in hematology and oncology are clearly visible, several questions remain. For example, it remains unknown how precision medicine tools can be implemented in healthcare systems and whether all possible approaches are also affordable. In addition, there is a need to define terminologies and to relate these to specific and context-related tools and strategies in basic and applied science. To discuss these issues, a working conference was organized in September 2019. The outcomes of this conference are summarized herein and include a proposal for definitions, terminologies, and applications of precision and personalized medicine concepts and tools in hematologic neoplasms. We also provide proposals aimed at reducing costs, thereby making these applications affordable in daily practice.
Identifiants
pubmed: 33623882
doi: 10.1097/HS9.0000000000000536
pmc: PMC7892291
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e536Subventions
Organisme : Austrian Science Fund FWF
ID : I 4154
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : I 4156
Pays : Austria
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Eur J Clin Invest. 2010 Oct;40(10):918-31
pubmed: 20597967
Blood. 2007 Dec 1;110(12):4055-63
pubmed: 17720881
J Transl Med. 2020 Apr 28;18(1):180
pubmed: 32345312
Surg Oncol Clin N Am. 2020 Jan;29(1):115-125
pubmed: 31757308
J Mol Biol. 2018 Sep 14;430(18 Pt A):2875-2899
pubmed: 29908887
Med Health Care Philos. 2016 Sep;19(3):423-30
pubmed: 26951521
Nature. 1952 Mar 1;169(4296):362
pubmed: 14919570
Sci Rep. 2014 Jun 05;4:5193
pubmed: 24898935
Blood Rev. 2017 Jan;31(1):63-76
pubmed: 27639498
Eur J Cancer. 2018 Nov;104:9-20
pubmed: 30296736
Int J Mol Sci. 2019 Feb 12;20(3):
pubmed: 30759825
Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):323-34
pubmed: 25971713
Cell. 2015 Feb 26;160(5):977-989
pubmed: 25723171
Leukemia. 2009 Mar;23(3):477-85
pubmed: 19039322
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563
pubmed: 28784769
Br J Haematol. 2013 Jul;162(2):250-62
pubmed: 23682827
Blood Rev. 2017 Nov;31(6):418-425
pubmed: 28797519
Cancer Discov. 2013 Dec;3(12):1416-29
pubmed: 24056683
Genome Med. 2020 Jan 14;12(1):8
pubmed: 31937368
Oncotarget. 2017 May 5;8(34):56338-56350
pubmed: 28915594
Blood. 2008 Dec 15;112(13):4808-17
pubmed: 19064740
Haematologica. 2005 Apr;90(4):534-41
pubmed: 15820950
Clin Transl Sci. 2017 Mar;10(2):61-63
pubmed: 28083940
Front Oncol. 2019 Jul 03;9:603
pubmed: 31334123
J Clin Oncol. 2011 Feb 1;29(4):369-77
pubmed: 21172891
Blood Adv. 2019 Jun 25;3(12):1837-1847
pubmed: 31208955
Hemasphere. 2020 Jun 08;4(3):e412
pubmed: 32647808
Transl Res. 2009 Dec;154(6):277-87
pubmed: 19931193
J Exp Clin Cancer Res. 2018 Jul 21;37(1):163
pubmed: 30031396
Leukemia. 2016 Sep;30(9):1861-8
pubmed: 27211271
Value Health. 2013 Sep-Oct;16(6 Suppl):S4-9
pubmed: 24034312
EBioMedicine. 2019 Jan;39:612-620
pubmed: 30545798
Nat Commun. 2018 Jan 3;9(1):42
pubmed: 29298978
Nat Rev Drug Discov. 2004 Sep;3(9):797-801
pubmed: 15340389
J Clin Oncol. 2010 Nov 20;28(33):4877-83
pubmed: 20921468
Per Med. 2013 Jul 1;10(5):453-462
pubmed: 24039624
J Med Chem. 2010 Jun 24;53(12):4701-19
pubmed: 20513156
Am Soc Clin Oncol Educ Book. 2019 Jan;39:411-420
pubmed: 31099617
Crit Rev Oncol Hematol. 2019 Apr;136:70-78
pubmed: 30878131
EBioMedicine. 2017 Dec;26:17-24
pubmed: 29203377
Leukemia. 2014 Jul;28(7):1449-58
pubmed: 24402164
Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8
pubmed: 17684099
Hemasphere. 2020 Sep 08;4(5):e474
pubmed: 32984771
BMC Med Ethics. 2013 Dec 21;14:55
pubmed: 24359531
Nature. 2018 Mar 15;555(7696):371-376
pubmed: 29489755
Nature. 2015 Oct 22;526(7574):525-30
pubmed: 26466571
Adv Biochem Eng Biotechnol. 2014;145:189-214
pubmed: 25216956
Per Med. 2014 Mar;11(2):197-210
pubmed: 29751382
Sci Transl Med. 2015 Jun 3;7(290):290ps13
pubmed: 26041702
Front Oncol. 2019 Dec 17;9:1417
pubmed: 31921674
J Clin Pharmacol. 2005 Nov;45(11):1218-20
pubmed: 16239353
Leuk Res. 2019 Mar;78:3-11
pubmed: 30641417
Int J Mol Sci. 2019 Jun 18;20(12):
pubmed: 31216696
Mol Cancer. 2015 Dec 11;14:207
pubmed: 26654227
BMC Med Ethics. 2016 Jul 18;17(1):43
pubmed: 27431285
Nat Rev Clin Oncol. 2018 Jul;15(7):405-406
pubmed: 29735987
Health Aff (Millwood). 2018 May;37(5):694-701
pubmed: 29733705
Leukemia. 2019 Jul;33(7):1747-1758
pubmed: 30635634
N Engl J Med. 2004 Mar 11;350(11):1079-80
pubmed: 15014180
Nat Biotechnol. 2007 Sep;25(9):1035-44
pubmed: 17721511
Cancer Treat Rev. 2019 May;75:52-61
pubmed: 31003190
Clin Cancer Res. 2010 Jul 15;16(14):3721-33
pubmed: 20525753
Leukemia. 2017 Nov;31(11):2388-2397
pubmed: 28757617
Br J Haematol. 2020 May;189(4):672-683
pubmed: 32068246
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Nat Rev Clin Oncol. 2017 Mar;14(3):141-154
pubmed: 27752053
Nat Immunol. 2008 Jul;9(7):705-12
pubmed: 18563076
Pharmgenomics Pers Med. 2019 Aug 02;12:167-179
pubmed: 31447578
Cancers (Basel). 2020 Jan 11;12(1):
pubmed: 31940809
J Leukoc Biol. 2020 May;107(5):859-870
pubmed: 32293060
Expert Rev Hematol. 2014 Oct;7(5):683-90
pubmed: 25169217
Leukemia. 2016 Aug;30(8):1638-47
pubmed: 27133824
Lancet Haematol. 2017 Dec;4(12):e595-e606
pubmed: 29153976
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
J Innate Immun. 2016;8(2):111-20
pubmed: 26845587
Nature. 2019 Jun;570(7762):474-479
pubmed: 31142838
Blood Cancer J. 2015 May 01;5:e309
pubmed: 25933373
JAMA Oncol. 2015 Sep;1(6):820-8
pubmed: 26181162
Hastings Cent Rep. 2010 Sep-Oct;40(5):14-6
pubmed: 20964158
Per Med. 2009 Jan;6(1):1-5
pubmed: 29783381
New Genet Soc. 2019 Jul 12;38(3):308-330
pubmed: 31708685
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582